<SEC-DOCUMENT>0001053691-17-000014.txt : 20170515
<SEC-HEADER>0001053691-17-000014.hdr.sgml : 20170515
<ACCEPTANCE-DATETIME>20170515165302
ACCESSION NUMBER:		0001053691-17-000014
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170515
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170515
DATE AS OF CHANGE:		20170515

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Diffusion Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001053691
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				300645032
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37942
		FILM NUMBER:		17845220

	BUSINESS ADDRESS:	
		STREET 1:		2020 AVON COURT
		STREET 2:		SUITE 4
		CITY:			CHARLOTTESVILLE
		STATE:			VA
		ZIP:			22902
		BUSINESS PHONE:		(434) 220-0718

	MAIL ADDRESS:	
		STREET 1:		2020 AVON COURT
		STREET 2:		SUITE 4
		CITY:			CHARLOTTESVILLE
		STATE:			VA
		ZIP:			22902

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RestorGenex Corp
		DATE OF NAME CHANGE:	20140307

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Stratus Media Group, Inc
		DATE OF NAME CHANGE:	20080722

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FERIS INTERNATIONAL, INC.
		DATE OF NAME CHANGE:	20080228
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>dffn-form8xk2017q1financia.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s14AB69ECF5E57AAD9C22C9CFF978BF45"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Washington, D.C.  20549</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">__________________</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM 8-K</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CURRENT REPORT</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Pursuant to Section 13 or 15(d) of</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">the Securities Exchange Act of 1934</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">__________________</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Date of Report (Date of earliest event reported):  May 15, 2017</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">___________________</font></div><div style="line-height:120%;text-align:center;font-size:20pt;"><font style="font-family:inherit;font-size:20pt;font-weight:bold;">DIFFUSION PHARMACEUTICALS INC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;padding-left:1px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.57258064516128%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">000-24477</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">30-0645032</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or other jurisdiction of incorporation)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Commission File</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(I.R.S. Employer</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;text-indent:57px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.37096774193549%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">2020 Avon Court, #4</font></div><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Charlottesville, Virginia</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">22902</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of principal executive offices)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Zip Code)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">(434) 220-0718</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Registrant&#8217;s telephone number, including area code)</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Not applicable</font></div><div style="line-height:120%;padding-bottom:32px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Former name or former address, if changed since last report)</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></div><div style="line-height:100%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div><div style="line-height:100%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div><div style="line-height:100%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div><div style="line-height:100%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><a name="sC4E621B4F7FB414967B9C9CFF99E1025"></a></div><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 2.02 &#8211; Results of Operations and Financial Condition</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 15, 2017, Diffusion Pharmaceuticals Inc. (the &#8220;Company&#8221;) issued a press release announcing its financial results for its first quarter ended March 31, 2017. A copy of that press release and the attached financial schedules are attached as Exhibit&#160;99.1 to this report and incorporated herein by reference.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information in this report (including Exhibit&#160;99.1) is being furnished pursuant to Item 2.02 and shall not be deemed to be &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;&#160;&#160;&#160;&#160;9.01 &#160;&#160;&#160;&#160;Financial Statements and Exhibits </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d)&#160;&#160;&#160;&#160;&#160;Exhibits. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:18%;"></td><td style="width:5%;"></td><td style="width:77%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibit&#160;Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Description</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Press release dated May 15, 2017, announcing financial results for the first quarter ended March 31, 2017.</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:32px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Dated:  May 15, 2017&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">DIFFUSION PHARMACEUTICALS INC.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">&#32;&#32;&#32;&#32;&#32;&#32;/s/ David G. Kalergis&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name: David G. Kalergis</font></div><div style="line-height:120%;text-align:justify;text-indent:288px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title:   Chief Executive Officer</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:62px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;</font></div><div><br></div><div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dffnq117earningsrelease.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sF41F1AAA2391FDD40871C9D6B62688CE"></a></div><div><div style="line-height:120%;text-align:left;"><img src="dffnq117earningsrelea_image2.jpg" alt="dffnq117earningsrelea_image2.jpg" style="height:74px;width:162px;"></div></div><div><br></div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">FOR IMMEDIATE RELEASE</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">NASDAQ: DFFN&#160;&#160;&#160;&#160;       </font></div><div style="line-height:120%;text-align:justify;text-indent:169px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:center;padding-left:6px;text-indent:6px;font-size:13.5pt;"><font style="font-family:inherit;font-size:13.5pt;font-weight:bold;">Diffusion Pharmaceuticals Provides Corporate Highlights and Reports  Financial First Quarter 2017 Results</font></div><div style="line-height:120%;text-align:left;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Charlottesville, Virginia (May 15, 2017)</font><font style="font-family:inherit;font-size:11pt;">&#32;- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN), a clinical stage biotechnology company focused on the development of novel small molecule therapeutics for cancer and other hypoxia-related diseases, today reported financial results for the three months ended March 31, 2017 and provided an overview of recent corporate highlights.</font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">David Kalergis, Chairman and Chief Executive Officer, stated, &#8220;With the completion of our recent private placement, we believe we are now well positioned to advance our clinical development strategy for our lead product candidate, trans sodium crocetinate (TSC).  We are in dialogue with the U.S. FDA regarding the design of a Phase 3 trial of TSC in newly diagnosed inoperable GBM patients, and plan to complete a protocol review in the third quarter of 2017. Assuming FDA sign-off on final protocol design, the study is planned to initiate by the end of 2017.&#8221;</font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Corporate Highlights</font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In March 2017, U.S. Patent 9,604,899 entitled &#8220;Bipolar Trans Carotenoid Salts and Their Uses&#8221; was granted by the United States Patent and Trademark Office. This patent expands the coverage of the therapeutic use of TSC and other related compounds to five hypoxia-related conditions including congestive heart failure, chronic renal failure, acute lung injury (ALI), chronic obstructive pulmonary disease (COPD) and respiratory distress syndrome (RDS).</font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In March 2017, the Company raised aggregate gross proceeds of $25.0 million in an oversubscribed private placement of its Series A convertible preferred stock. At March 31, 2017, the Company had cash and cash equivalents of </font><font style="font-family:inherit;font-size:11pt;">$12.2 million</font><font style="font-family:inherit;font-size:11pt;">&#32;and a </font><font style="font-family:inherit;font-size:11pt;">$8.3 million</font><font style="font-family:inherit;font-size:11pt;">&#32;subscription receivable that was received on April 3, 2017.</font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Three Months Ended March 31, 2017 Financial Results</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Research and development expenses were $1.0 million for the three months ended March 31, 2017, compared to $2.4 million for the three months ended March 31, 2016.  This decrease in research and development was attributable to a decrease in expenses related to the Company&#8217;s pancreatic cancer program and animal toxicology studies. </font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">General and administrative expenses were $1.6 million for the three months ended March 31, 2017, compared to $3.9 million for the three months ended March 31, 2016. The decrease in general and administrative expenses was primarily attributable to a decrease in costs attributable to the reverse merger transaction in January 2016.</font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">We recognized </font><font style="font-family:inherit;font-size:11pt;">$26.0 million</font><font style="font-family:inherit;font-size:11pt;">&#32;in warrant related expenses (of which $25.6 million was non-cash related and fees netted against gross proceeds) associated with the private placement for the three months ended March 31, 2017, which consisted of the change in fair value of the common stock warrants from issuance, </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">the excess fair value of the common stock warrants over the gross cash proceeds from the Series A preferred stock offering, and placement agent  commissions and other offering costs.</font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Net loss was </font><font style="font-family:inherit;font-size:11pt;">$28.6 million</font><font style="font-family:inherit;font-size:11pt;">&#32;for the three months ended March 31, 2017, compared to a net loss of $6.2 million for the three months ended March 31, 2016.  For the quarter ended March 31, 2017, the net loss included </font><font style="font-family:inherit;font-size:11pt;">$26.0 million</font><font style="font-family:inherit;font-size:11pt;">&#32;in warrant related expenses (of which $25.6 million was non-cash related and fees netted against gross proceeds) associated with the private placement. For the three months ended March 31, 2017, net loss attributable to common shares was </font><font style="font-family:inherit;font-size:11pt;">$28.7 million</font><font style="font-family:inherit;font-size:11pt;">, which was  inclusive of the dividend payable on the Series A convertible preferred stock.</font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Net cash used in operating activities for the three months ended March 31, 2017 was $3.4 million compared to $4.6 million during the three months ended March 31, 2016.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">About Diffusion Pharmaceuticals Inc.</font></div><div style="line-height:120%;text-align:justify;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Diffusion Pharmaceuticals Inc. is a clinical stage biotechnology company focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard of care treatments including radiation therapy and chemotherapy. Diffusion is developing its lead product candidate, trans sodium crocetinate (TSC), for use in the many cancer types in which tumor hypoxia (oxygen deprivation) is known to diminish the effectiveness of current treatments. TSC targets the cancer's hypoxic micro-environment, re-oxygenating treatment-resistant tissue and making the cancer cells more vulnerable to the therapeutic effects of treatments such as radiation therapy and chemotherapy, without the apparent addition of any serious side effects.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">A Phase 2 clinical program, completed in the second quarter of 2015, evaluated 59 patients with newly diagnosed glioblastoma multiforme (GBM). This open label, historically controlled study demonstrated a favorable safety and efficacy profile for TSC combined with standard of care, including a 37% improvement in overall survival over the control group at two years.  A particularly strong efficacy signal was seen in the subset of inoperable patients where survival of TSC-treated patients at two years was increased by 380% over the controls. At an End-Of-Phase 2 Meeting, the U.S. Food and Drug Administration provided Diffusion with extensive guidance on the design for a Phase 3 trial of TSC in newly diagnosed GBM patients.   Assuming FDA sign-off on our final protocol design, focusing on the inoperable patients, the study is planned to initiate by the end of 2017.  Due to its novel mechanism of action, TSC has safely re-oxygenated a range of tumor types in our preclinical and clinical studies.  Diffusion believes its therapeutic potential is not limited to specific tumors, thereby making it potentially useful to improve standard-of-care treatments of other life-threatening cancers.  Additional planned studies include a Phase 2 trial in pancreatic cancer and a study in brain metastases, with study initiation subject to receipt of additional funding or collaborative partnering.  The Company also believes that TSC has potential application in other indications involving hypoxia, such as neurodegenerative diseases and emergency medicine, and an in-ambulance trial of TSC in stroke is under consideration.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Forward-Looking Statements</font></div><div style="line-height:120%;text-align:justify;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:10px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">To the extent any&#160;statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the company's plans, objectives, expectations&#160; and intentions with respect to future operations and products, the potential of the company's technology and product </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;padding-left:10px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">candidates, the anticipated timing of future clinical trials and protocol review, the anticipated financial position, operating results and growth prospects of the company and other statements that are not historical in nature, particularly those that utilize terminology such as "would," "will," "plans," "possibility," "potential," "future," "expects," "anticipates," "believes," "intends," "continue," "expects," other words of similar meaning, derivations of such words and the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause the company's actual results to be materially different than those expressed in or implied by such forward-looking statements. Particular uncertainties and risks include: general business and economic conditions; the company's need for and ability to obtain additional financing; and the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance. All forward-looking statements in this news release speak only as of the date of this news release and are based on management's current beliefs and expectations. Diffusion undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.</font></div><div style="line-height:120%;text-align:justify;padding-left:10px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Diffusion Pharmaceuticals Contacts</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;background-color:#ffffff;">David Kalergis</font></div><div style="line-height:120%;text-align:justify;padding-left:8px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;background-color:#ffffff;">Chief Executive Officer Diffusion Pharmaceuticals Inc. </font></div><div style="line-height:120%;text-align:justify;padding-left:8px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;background-color:#ffffff;">(434) 220-0718</font></div><div style="line-height:120%;text-align:justify;padding-left:8px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">dkalergis@diffusionpharma.com</font></div><div style="line-height:120%;text-align:justify;padding-left:8px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;background-color:#ffffff;">Stephanie Carrington ICR Inc.</font></div><div style="line-height:120%;text-align:justify;padding-left:8px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;background-color:#ffffff;">(646) 277-1282</font></div><div style="line-height:120%;text-align:justify;padding-left:8px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Stephanie.Carrington@icrinc.com</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>dffnq117earningsrelea_image2.jpg
<TEXT>
begin 644 dffnq117earningsrelea_image2.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" "M 9\# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#_-+\7_C1XN_: \?7WBKQQXDUKQ7XBU$@W&H:I=O<SN!]U0S$[44<*@PJ@
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M_P"#J#]J7XG?L\_%CX06_@#XC>// ]OJ>DZC)>1>']?N],2[=9H0K2"&10Y
M) )SC)K\.;N[EO[J2>>22::9R\DDC%FD8G)))Y))YR: BC];O^#4']C_ ,$_
M&OXL?$SXB>+=!M->U+X>KI4'AY+V&.>UL[BX>YDDN1&ZG_2(_LT/ER C9YCD
M MM*_O8=%LVU:._^R6OVZ*)K=+GRE\Y(V*LR!L9"DHA(S@E%]!7\;/P<_:;^
M)/[.Z:@OP_\ B%XX\"KJYC-\/#VNW6F"],>[R_-\AUW[=[[=V<;VQC)KMO\
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MS\?_ -OKQ=H_CSXH?$3QMI%K\/[R]AL=>\27FI6T4ZZCIJ+*L<TC*) LCJ&
MR [#.":\?_X+T?MQ_&OX/?\ !6'XK>'/"/Q@^*7A;P]IW]D?9-+TCQ7?V-G:
M[]'L9'\N&*547<[NYP!EF8GDDT$6/Z/**_G)_P""!O[</QJ^,?\ P5:^&/AW
MQ=\7_BAXJ\/ZA'JQNM,UCQ5?7UG<[-)O)$WPRRLC;756&0<,H(Y K^C:@6P4
M5_.'_P %Z?VX_C7\'O\ @K!\5O#GA'XP?%+PMX>T[^R/LFEZ1XKO[&SM=^CV
M,C^7#%*J+N=W<X RS,3R2:]@_P"#8']KWXM?'_\ ;Y\7:/X\^*'Q$\;:/:^
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MT1?\&D\;)_P3A\:%E90WQ(OBI(ZC^S-+''X@_E7\[M?U<?\ !#GX!7_[-_\
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M-TS7;59M-T6P+.L&VW):.X>>/;.9)5.U7B5$0H[R_@6.M?UY_P#!+[_E&U\
M?^R>:%_Z;X*Z3PY'Y+_\'+/_  26^&7[,'PQ\._&;X6Z!#X/&I:\FA:]HFFP
ML--<S0S2Q7<:9VVNTP&)D0"-C+&0$8,9/QVCE:&171F5E.593@J?4&OZ:O\
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MUN\T8^W+)Y+.N59T0X9<JI.*]O\ ^">'_!??]FG_ (*7^*M+\*^ _%VH:/\
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M6\55,MC>1!F\JXCW+E<E65DD1I(I(Y&\@_X(J?\ !5O_ (?!_LL:_P#$S_A
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MOQZ^(=FNI:%X.T3_ $2$VAF>,SW%XR.(EVP7C@I'+L%I(TOD1E9#\K_MD?\
M*Y)^R=_V2J^_])O%==]_P5(_X)X_M,> O^"B6C?M??LBCP/X@\:0^%4\*^)O
M!?B%O+.OQB<!9(I9I8XMIC:,NHFM606"E'F:9T !]!?\$]?^"DWQ,_:M^+OB
M+P#\5OV6OBM\ _$>AV+ZI#J.HM_:OAG48%-JHBBU18H8WNR;DGR8T<!(9"9
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MPPF9UBW/"EXY1!*R--Y8#_JU_P +9\*_\*L_X3K_ (2;P_\ \(3_ &5_;O\
MPD/]HP_V5_9WD^?]L^T[O*^S^3^\\W=LV?-G'-?(_P#P<9^'K/Q/_P $4OC]
M;7T/GPQZ+;7:KO9<2P:A:S1-E2#\LD:-CH<8(()%?G'\4OVHO'B?\&47@W4E
MEUW4M1UZ&/P3>:K82M:MH^CV_B"XLXUE,*8,#6MG#8,KE1(MT [.6*N ?5A_
MX.4=0_:5^)5YH?[)?[,/Q1_:0TK1)98-6\1FY_X1K1X6 5HO*FE@FSYB[R%N
M!;R?(-J/DE?LC_@FY^V/XP_;?_9]NO%GCOX*^.O@+XFT[6KG1[KPUXGBE$L@
MC6*1+JWDDAA::W=9542>4H\R.91N"!VR/^",W@'1OAM_P28_9OT_0=/M]+L;
MCX=:)JLL, PKW5Y917EU*?\ :EN)YI&]6D-?2] !1110 4444 %%%% !1110
M 4444 %%%% !1110!^8G_! 7_@GE\8?V)_VL/VR?$WQ.\'_\(SHGQ6\6VFI^
M%KG^U;*]_M2W2\UF1GV6\TCQ82[MSB4(3YF,95@/T[HHH _-7_@M-^P!\7/V
MM/\ @HO^P[X\^'WA/_A(/"GP?\<)K'BZ^_M2RM?[(M1J>D3F3RYYDDF_=VL[
M;85=ODQC)4'[8_;C^'.M?&']BGXP>$?#EG_:/B'Q3X)UK2-+M/-2'[5=7%A-
M%#'OD947<[J-SL%&<D@9->I44 ?E+_P0P_X)-?%;X'?\$7_CI^S]\9-';X:^
M)/BMJGB"S@D%W9ZP;2SU'1+.P6[ M9WC;:Z2GRS(K'R^=H8-7(?\$TO#G_!1
M'_@F[^RO9_LXZ;^S#\-_%5GX9U:^T_PS\0[KXAV=KHMG!=7TT[7UY9*[7MU;
MK+/+*%C2WG,.U/)\T'/[$T4 ?EK_ ,$ /^"<G[07_!/7]K;]J2Z^.%C:^))/
MBY>:7X@M_'FD7]G)IFO7J27T]YFWWQW<,K2:CG#6J19@F ;;Y1DP?^"7?_!,
MOXW_ +.O_!P7^TS\</&7@G^Q_A?\0K'7H= UK^V+"X^WO<ZSI]S /L\4[SQ[
MH8)6_>1J!MP<$@']:** /@__ (.-OV,OB5^WE_P32U/X?_"CPW_PE7BZX\0:
M;?1V']H6MCNAB=C(WF7,L<? (X+9/8&OI#_@GM\+=>^!W[ OP/\ !/BFQ_LO
MQ-X/^'^@Z)J]GYT<_P!DO+;3K>&>+S(V:-]LB,NY&93C()&#7L%% 'Y7_P#!
MN9_P3@^-'[!WQZ_:QUKXK>#?^$5TSXF:_IM[X;F_M:QOO[2ABN-7>1MMM-(T
M>%NH#B4(3YG .&P?\%D?^"<'QH_:K_X*]?L=_%'P#X-_M[P+\*]?TJ]\4:G_
M &M8VO\ 9<,.M6]U*WE33)++MA1FQ$CDXP 3@5^J%% 'Y>_\%??^"?W[0I_X
M*>? O]L#]G/P_P"'_B3XF^&^E-X6U7P9J6HP:6\UHQO]T\4\\D<1#PZC<Q-E
M@\3K ZI,"XC\'_X+#_L<?\% /^"SO[-D<.I?"#P'\(_#?@?4X]2TSX;#QI9:
MSXB\3ZE^[@%\VH!4LH[:*VNKS9$9H7W+-O24FW*_MU10!\7_ /!4C_@F3_P]
MI_X)DZ=\-=3:Z\"^-+&"P\1:$NI2)(NC:S#:/&+>\^S/+&Z;)YX)&A>55+^8
MGF[%#?/?[+'[0_\ P4V_98^$4GP]\>_LM:#\?M5\*R2:9I/CRW^*>DZ0VLVT
M64AN+F.X9IKAF #"21+>5TV^:@EWNWZJ44 ?!O[5W_!._P ?_P#!8G_@D/I/
M@']HBP\*?#_XX3E?$,1\/33W&E>&M8BDG6W&T3OYH-G,T$RF29%:>5HRQ2)Q
MY/\ LP_M*_\ !3']F7X:MX#^(/[*/AWX]:AX7D;3--\;Z=\5-*T1M<MH1Y<=
MS.ERTDLSR;=_F.EO(RLOF1+)O)_4JB@#PW_@GW\0?CU\4/@9=ZQ^T1X \*?#
M/QM<:W>"QT#0]4&I"TTL%1;?:)DDDC:X/[S<8G*,H1ML;,T2?EG\#O\ @G3^
MV5_P1!_X* ?%K4/V8?A+X1^-GP&^*DZ:DNF7/B.UTB?2XTDNGM;+S+V[$ZSV
MAG>,R_OX[B%D9MLK%8/V^HH _"OX]?\ !*#]MS]JS_@I1^RK^TM\5-$\&ZIK
M.C^+]&N/$GASPM?6EMIWPTT'3[^PNXHVDN)Q+>7+R3:G)+Y+7(#1 1R,C11I
M]Q?\'&/_  34\:?\%0_^">!\&_#NYL_^$R\(^(K;Q;IFF712*/7WAMKJV:S$
M[NJ0.R7;NCOE"\2HQ17,L?WE10!\N?\ !,?XW?M0?%SPGK5K^TU\%-'^$VKZ
M%::;%I]]IWB6RU:/Q/.R3"]E\FVED^RA&CA8(S'(N, ML)KY'_X-7?\ @FM\
M:_\ @F_\(_B]I?QH\%_\(;?>*-8T^ZTR+^U[#4?M,<4,RR-FTGE"X9E&&()S
MQFOU;HH _&WX6?\ !.K]KK_@AW^U_P")KO\ 93\(Z3\=OV:?B-?7&IW/PYOO
M%,&CW'AB;Y/+,=Q?2_)*%VPK.AG,T,.+B/?'!*/M?]AW]H?]K[XY_M*:]_PN
MC]GOPC\"_A+9^'@=-C'B^U\2ZY?:P;B,#]_:RB(6P@\XE6MT8/Y>)'!8+]=T
M4 ?BO_P3<_9I_;F_X(9:=\4O@_X%_9T\,_M%?#74?$DNO>&_%5MX[TWPS-/)
M+;6\/F3074K2;?+MX%:#RTV2I-MFFC9'KOO^":?_  3E_:L_9R_X+I?$#X\_
M':Q\*^-++XO>![FPOO$W@N_A32- O&N;%X+$VUV\-[Y4-OIJ0(Z0SDB2W+NS
M&9X_UJHH _.#]I;]@KXL?$#_ (.6_P!GO]H'2/"GVSX1>!_A_=Z)K>O?VG9Q
M_8KQX/$"+%]F:47+Y:^M1N2)E_>]?E;;Z!^UE^TY^W+\%?VR-0L_AG^S-X#^
M-7P-;2H)-/NK7QM:^'M<^V,H\U9Y;R;8H219,)':N&1XF\X-OC7[?HH _*W_
M ()V_P#!-7X^_'3_ (*MZ[^VA^U3H7AWX=^)-'L9-#\#>!=%U"+4'TR)K=[4
MW%Q<P2/$ZBWEG4 N[2RW,C[;=(8HV_5*BB@#\POV(O\ @GA\8OA#_P ''?[1
MOQZ\1>#_ .S_ (3^//"<VF:%KO\ :ME-]NN&FT9@GV>.9KB/(M+@YDC4?N^O
MS+G>_:6_8*^+'Q _X.6_V>_V@=(\*?;/A%X'^']WHFMZ]_:=G']BO'@\0(L7
MV9I1<OEKZU&Y(F7][U^5MOZ/T4 ?,_\ P6/_ &??%_[5?_!,?XP?#WP#I']O
M>,/%6BK::7I_VJ&U^U2^?$^WS)G2-?E5CEV XZUX/_P3I_X)/7?B3_@WZ\-_
MLK_M$>';[P_?7]GJMMK=A9:K!)<Z;(^NW>H65Q%<6TDD+21L;:=1N="5"2(R
M[XS^B%% 'Y$_L3>"?^"AG_!(3PW=?!33_@SX7_:P^$GAF:7_ (0WQ%:^-]/\
M*ZA:6;R,R6THO'9]J_?\HQR>49&C2XEB2,)]-6GQ4_;B^,'_  3>^,FK/\+_
M  '\(_VC!?W$/P^T&36+75K==/$5H1+)<+-+;27Q+7XB,HC@\Q+;S8Q'O9OM
MRB@#Y_\ ^"6__"]_^&%/ _\ PTQC_A=F;_\ X2+']G]/[0N?LO\ R#_]%_X]
M/L_^J_X%\^ZOH"BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
+"BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
